Literature DB >> 17707755

Essential hypertension.

Franz H Messerli1, Bryan Williams, Eberhard Ritz.   

Abstract

Essential hypertension can be defined as a rise in blood pressure of unknown cause that increases risk for cerebral, cardiac, and renal events. In industrialised countries, the risk of becoming hypertensive (blood pressure >140/90 mm Hg) during a lifetime exceeds 90%. Essential hypertension usually clusters with other cardiovascular risk factors such as ageing, being overweight, insulin resistance, diabetes, and hyperlipidaemia. Subtle target-organ damage such as left-ventricular hypertrophy, microalbuminuria, and cognitive dysfunction takes place early in the course of hypertensive cardiovascular disease, although catastrophic events such as stroke, heart attack, renal failure, and dementia usually happen after long periods of uncontrolled hypertension only. All antihypertensive drugs lower blood pressure (by definition) and this decline is the best determinant of cardiovascular risk reduction. However, differences between drugs exist with respect to reduction of target-organ disease and prevention of major cardiovascular events. Most hypertensive patients need two or more drugs for blood-pressure control and concomitant statin treatment for risk factor reduction. Despite the availability of effective and safe antihypertensive drugs, hypertension and its concomitant risk factors remain uncontrolled in most patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707755     DOI: 10.1016/S0140-6736(07)61299-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  168 in total

1.  [Analysis of the rational use of anti-hypertensives in the Murcia (Spain) region].

Authors:  Juan C Ruiz; María A Ariza; Belén Aguilera; Mariano Leal; Ramón Gómez; José Abellán
Journal:  Aten Primaria       Date:  2012-01-31       Impact factor: 1.137

Review 2.  Hypertension and cerebrovascular dysfunction.

Authors:  Costantino Iadecola; Robin L Davisson
Journal:  Cell Metab       Date:  2008-06       Impact factor: 27.287

3.  Identifying common genetic variants in blood pressure due to polygenic pleiotropy with associated phenotypes.

Authors:  Ole A Andreassen; Linda K McEvoy; Wesley K Thompson; Yunpeng Wang; Sjur Reppe; Andrew J Schork; Verena Zuber; Elizabeth Barrett-Connor; Kaare Gautvik; Pål Aukrust; Tom H Karlsen; Srdjan Djurovic; Rahul S Desikan; Anders M Dale
Journal:  Hypertension       Date:  2014-01-06       Impact factor: 10.190

4.  Hypertension is associated with cognitive decline in elderly people at high risk for dementia.

Authors:  Michael Wysocki; Xiaodong Luo; James Schmeidler; Karen Dahlman; Gerson T Lesser; Hillel Grossman; Vahram Haroutunian; Michal Schnaider Beeri
Journal:  Am J Geriatr Psychiatry       Date:  2012-02       Impact factor: 4.105

5.  C-C Motif Chemokine Receptor 7 Exacerbates Hypertension Through Effects on T Lymphocyte Trafficking.

Authors:  Yi Wen; Nathan P Rudemiller; Jiandong Zhang; Xiaohan Lu; Jiafa Ren; Jamie R Privratsky; Robert Griffiths; Junyi J Zhang; Gianna E Hammer; Steven D Crowley
Journal:  Hypertension       Date:  2020-01-27       Impact factor: 10.190

Review 6.  Success and failure of vaccines against renin-angiotensin system components.

Authors:  Morris J Brown
Journal:  Nat Rev Cardiol       Date:  2009-08-25       Impact factor: 32.419

Review 7.  Device-based therapies for arterial hypertension.

Authors:  Lucas Lauder; Michel Azizi; Ajay J Kirtane; Michael Böhm; Felix Mahfoud
Journal:  Nat Rev Cardiol       Date:  2020-04-14       Impact factor: 32.419

8.  Hypertension in women: latest findings and clinical implications.

Authors:  Helga Gudmundsdottir; Aud Høieggen; Aud Stenehjem; Bård Waldum; Ingrid Os
Journal:  Ther Adv Chronic Dis       Date:  2012-05       Impact factor: 5.091

9.  Interindividual variation in serum sodium and longitudinal blood pressure tracking in the Framingham Heart Study.

Authors:  Rodrigo M Lago; Michael J Pencina; Thomas J Wang; Katherine J Lanier; Ralph B D'Agostino; William B Kannel; Ramachandran S Vasan
Journal:  J Hypertens       Date:  2008-11       Impact factor: 4.844

Review 10.  Is epistaxis associated with arterial hypertension? A systematic review of the literature.

Authors:  D Kikidis; K Tsioufis; V Papanikolaou; K Zerva; A Hantzakos
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-29       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.